September 5, 2008
Medivisor Inc. To Market Albumax
Medivisor, Inc. (PINKSHEETS: MVSR) announced today that it has signed an agreement with Cura Pharmaceutical, Co. Inc to market the product Albumax, a whey protein isolate formula that makes it easy for kidney disorder patients to reach their daily requirements of high quality protein in their diet. Under the terms of the Agreement, Cura will continue to be responsible for manufacturing, regulatory, medical, clinical development, pricing and distribution for the product while Medivisor is responsible for sales and marketing.
Kidney disease affects as many as 26 million people, report researchers at Johns Hopkins University in Baltimore, Tufts-New England Medical Center in Boston and Cleveland Clinic Foundation. Their findings are published in the Journal of the American Medical Association. Kidney disease can lead to kidney failure. It heightens the risk of heart attack, stroke, high blood pressure and premature death. It causes anemia, bone disease and malnutrition. According to the National Institutes of Health's US Renal Data System, by 2020, nearly 785,000 people will be receiving treatment for kidney failure, costing $53.6 billion.
Protein malnutrition is common in dialysis patients and is a major contributing factor to morbidity and mortality of these patients. When a patient relies on dialysis to survive, his nutritional status may suffer because of his disease, co-existing conditions, and the dialysis therapy itself. The primary nutrition risk for dialysis patients is protein malnutrition. Dialysis depletes proteins and amino acids from the blood. Depleted protein levels in the patient's blood will cause the body to break down muscle tissue to obtain protein. Dietary allowance for protein for dialysis patients is 1.2gm/kg/day two-thirds more than in a healthy person. According to the National Kidney Foundation, serum albumin is a valid and clinically useful measure of protein-energy nutritional status in maintenance dialysis patients. A higher serum albumin level is indicative of better protein nutritional status; the goal is to exceed the lower limit of the normal range of 4.0g/dL.
A small pilot study of Albumax showed that patient's serum albumin levels consistently increased while taking Albumax and dropped when they discontinued use of Albumax. Of the patients that discontinued Albumax and then restarted, their serum albumin decreased when Albumax was discontinued and showed increases upon restarting Albumax.
Due to the nature of the dialysis patient's metabolic condition, nutrition must be closely monitored. Competitive products formulated specifically for dialysis patients are limited. It has been reported by The National Kidney Foundation that nutritional interventions that maintain or increase serum albumin concentrations may be associated with improved long-term survival.
"We are extremely pleased that Cura has chosen Medivisor as their partner in developing the market for this product in the United States," stated Dino Luzzi, CEO of Medivisor. "With the announcement of this Agreement we also launched www.albumax.net which has given the product a web presence. Over the next few weeks our next initiatives will be to work with the individual state reimbursement divisions of Medicaid to define Albumax as a special nutritional composition which is essential for the dietary management of the disease process."
About Medivisor Inc.:
Medivisor, Inc. is a rapidly growing developer of next-generation focus driven marketing tools. The company is dedicated to providing technologies that offer innovative and competitive advantages to the bioscience and pharmaceutical markets and beyond. From pre-product development through product launch and commercialization, Medivisor offers worldwide experience in delivering effective and successful integrated marketing and creative communications campaigns for the mutual benefit of its clients. www.medivisor.com
About Cura Pharmaceutical, Co. Inc.:
Cura Pharmaceutical Co., Inc is a New Jersey-Based pharmaceutical marketing company that focuses on select niche markets through the offering of specialty products and services. Cura's strategy is to provide products to the American Healthcare Practitioner and to create partnerships worldwide that satisfy a distinct unmet medical need and are cost effective. These products often are not readily accessible and provide enhancements to existing treatments. Cura's management team has extensive experience in the industry, with over 100 years of combined pharmaceutical experience.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") Additionally, words such as "seek,""intend,""believe,""plan,""estimate,""expect,""anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the performance ability of the initial units in the field. Further information on Medivisor risk factors is contained in its filings with the Securities and Exchange Commission. Medivisor does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact: Dino Luzzi CEO Medivisor, Inc. 326 Walt Whitman Road Huntington Station, N.Y. 11746 Tel: 631.549.7100 http://www.medivisor.com
SOURCE: Medivisor Inc.